SCHEDULE 13D/A: Apimeds Pharma Investors Challenge Merger, Allege Wrongdoing

Major shareholders of Apimeds Pharmaceuticals US, Inc. are challenging the validity of a recent merger with MindWave Innovations Inc., alleging potential wrongdoing by the board and management.

Summary

• Inscobee Inc. and Apimeds Inc. (the "Reporting Persons") filed an Amendment No. 1 to their Schedule 13D regarding their beneficial ownership in Apimeds Pharmaceuticals US, Inc. (the "Issuer").
• The amendment details a merger on December 1, 2025, where Apimeds Merger Sub, Inc. merged with MindWave Innovations Inc., making MindWave a wholly-owned subsidiary of the Issuer.
• MindWave stockholders received 7,477,017 shares of Series A convertible preferred stock, which, upon conversion, would represent 90.9% of the Issuer's total issued and outstanding common stock on a fully-diluted basis.
• Conversion of Series A Preferred Stock is contingent on stockholder approval and NYSE American LLC listing rules compliance.
• In connection with the merger, the Reporting Persons entered into a stockholder support and lock-up agreement and voting agreements.
• The Reporting Persons are now questioning the validity of representations made by the Issuer and MindWave regarding the merger, specifically concerning MindWave's digital assets.
• They have requested access to the Issuer's books and records to investigate potential wrongdoing by the Board and executive officers related to the merger and associated agreements.
• The Reporting Persons, who constitute the majority stockholders, reserve the right to pursue extraordinary corporate actions, including litigation and the removal or replacement of Board members and executive officers.
• Inscobee Inc. has not yet executed the actions by stockholder consent required by the Support & Lock-Up Agreement.

Sentiment

Score: 2

Explanation: The filing indicates significant internal conflict, allegations of wrongdoing, and potential litigation between major shareholders and company management following a merger. This creates substantial uncertainty and risk for the company and its investors.

Positives

• The Reporting Persons collectively hold a significant stake, with Inscobee Inc. owning 16.7% (2,099,747 shares) and Apimeds Inc. owning 34.3% (4,316,618 shares) of the Issuer's common stock, making them majority stockholders.
• The Reporting Persons are actively reviewing the validity of the Support & Lock-Up Agreement and Voting Agreements, indicating a proactive approach to protecting their investment.

Negatives

• Allegations of potential wrongdoing by the Issuer's Board and executive officers in connection with the merger and related transactions.
• The Reporting Persons are questioning the validity of representations made regarding MindWave's digital assets.
• Potential for significant corporate conflict, including litigation and attempts to remove and replace Board members and executive officers.
• Inscobee Inc. has not executed the stockholder consent actions required by the Support & Lock-Up Agreement, indicating a breakdown in agreement.
• The merger consideration involves Series A convertible preferred stock that, upon conversion, would dilute existing common stockholders significantly, with MindWave stockholders owning 90.9% on a fully-diluted basis.

Risks

• Litigation Risk: The Reporting Persons reserve the right to commence litigation related to the merger and associated agreements, which could be costly and disruptive.
• Corporate Governance Instability: Potential for removal and replacement of Board members and executive officers could lead to significant management instability and strategic shifts.
• Merger Uncertainty: The validity of the merger representations and the terms of the Support & Lock-Up and Voting Agreements are under review, creating uncertainty around the completed merger.
• Shareholder Dilution: The conversion of Series A Preferred Stock into common stock would result in substantial dilution for current common stockholders, with MindWave stockholders owning 90.9% on a fully-diluted basis.
• Regulatory Compliance Risk: The conversion of Series A Preferred Stock is contingent on NYSE American LLC listing rules approval, and any issues could impact the company's listing status or capital structure.
• Reverse Stock Split: A reverse stock split is contemplated as part of the agreements, which can sometimes be perceived negatively by the market.

Future Outlook

The Reporting Persons intend to continue reviewing their investment and the Issuer's business affairs. They may engage in further discussions with the Issuer's directors, officers, and other stockholders regarding management, operations, capitalization, and strategic plans. They explicitly reserve the right to formulate plans or proposals concerning extraordinary corporate actions, including litigation and changes to the Board and executive officers, if their concerns regarding the merger and digital assets are not resolved. The conversion of Series A Preferred Stock and a potential reverse stock split are contingent on future stockholder and NYSE approvals.

Management Comments

• The Reporting Persons have engaged in discussions with representatives of the Issuer, including the Issuer's executive officers and board of directors, and the management of MindWave regarding the validity of these representations and the digital assets.
• The Reporting Persons reserve the right to seek extraordinary corporate action, including but not limited to, commencement of litigation... and the removal and replacement all of all of a portion of the members of the Board and executive officers of the Issuer.
• The Reporting Persons are actively reviewing the validity of the Support & Lock-Up Agreement and the Voting Agreements.

Industry Context

This situation highlights increasing shareholder activism, particularly when significant corporate transactions like mergers occur. Shareholder challenges to merger terms, especially concerning valuations or representations of acquired assets (like digital assets), are becoming more common. The involvement of majority shareholders in questioning management decisions underscores the importance of robust corporate governance and transparency in M&A activities within the pharmaceutical and technology sectors.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The Reporting Persons reserve the right to commence litigation, including actions related to the merger and associated agreements, and the potential removal and replacement of Board members and executive officers.

Related Party Transactions

• The Merger Agreement between Apimeds Pharmaceuticals US, Inc. and MindWave Innovations Inc. (which became a wholly-owned subsidiary).
• Stockholder Support & Lock-Up Agreement and Voting Agreements entered into by the Reporting Persons with the Issuer and MindWave.

Stakeholder Impact

• Shareholders: Face significant uncertainty regarding the company's future direction, potential dilution from preferred stock conversion, and the risk of value erosion due to corporate conflict and potential litigation.
• Management/Employees: Current Board members and executive officers face potential removal, creating instability and uncertainty within the company.
• MindWave Innovations Inc. (now a subsidiary): Its integration and future operations could be impacted by the ongoing disputes and potential changes in the parent company's leadership.
• Creditors/Suppliers: May face increased risk perception due to corporate instability and potential legal battles.

Next Steps

• The Reporting Persons will continue their investigation into the validity of representations made regarding the merger and MindWave's digital assets.
• The Issuer's stockholders will need to vote on the approval of the issuance of common stock upon conversion of Series A Preferred Stock and a potential reverse stock split.
• NYSE American LLC approval is required for the conversion of Series A Preferred Stock and any new listing application resulting from a change in control or Reverse Merger.
• The Reporting Persons may initiate litigation or seek to remove/replace Board members and executive officers.

Key Dates

Recommendation

The filing reveals a severe breakdown in corporate governance and trust between the company's majority shareholders and its current management/board. Allegations of wrongdoing related to a significant merger, coupled with the explicit threat of litigation and management overhaul, create an extremely high level of uncertainty and risk. The potential for substantial dilution from the preferred stock conversion further exacerbates the negative outlook. Investors should consider divesting given the likelihood of prolonged conflict and potential value destruction.

Keywords

Apimeds Pharmaceuticals US, MindWave Innovations, Merger Agreement, Schedule 13D, Shareholder Activism, Corporate Governance, Litigation Risk, Preferred Stock Conversion, NYSE Listing Rules, Digital Assets